TrianglePUBLICATIONS · 30383140
Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- JAMA Oncol
- Publication date
- 2018 Dec 1
- First author
- Raut CP
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Raut CP
- type
- Author
- name
- Espat NJ
- type
- Author
- name
- Maki RG
- type
- Author
- name
- Araujo DM
- type
- Author
- name
- Trent J
- type
- Author
- name
- Williams TF
- type
- Author
- name
- Purkayastha DD
- type
- Author
- name
- DeMatteo RP
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Raut CP
- type
- Author
- name
- Espat NJ
- type
- Author
- name
- Maki RG
- type
- Author
- name
- Araujo DM
- type
- Author
- name
- Trent J
- type
- Author
- name
- Williams TF
- type
- Author
- name
- Purkayastha DD
- type
- Author
- name
- DeMatteo RP
- type
- Author
- bibliography ids
- nci-bib-09b9a74268ab98aca8c96249
- book metadata
- content sha256
- 97007dadb4703b2534282321562f87d9bf6a64ff48a50bd3efec7fae6411888e
- document type
- citation
- dois
- 10.1001/jamaoncol.2018.4060
- electronic publication date
- display
- 2018 Dec 13
- precision
- day
- year
- 2018
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:30383140
- immutable id
- pubmed:30383140@97007dadb4703b2534282321562f87d9bf6a64ff48a50bd3efec7fae6411888e
- journal
- abbreviation
- JAMA Oncol
- issn electronic
- 2374-2445
- issn print
- 2374-2437
- issue
- 12
- name
- JAMA oncology
- nlm unique id
- 101652861
- pages
- e184060
- volume
- 4
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 30383140
- provenance
- batch id
- 438b2803888025c6cf56
- provider
- NCBI PubMed ESummary
- record sha256
- 5cae4eff24785f64671274260ec9d036cb02c7af5b3695b65e7ba3545cdafcd1
- response sha256
- 0adf5ff07d3aa03a45feef5e4b7998e2ddea370eb9d1c6aa9134c5fd329767e6
- retrieved at
- 2026-09-09T23:47:36.359220+00:00
- publication date
- display
- 2018 Dec 1
- precision
- day
- year
- 2018
- publication types
- Clinical Trial, Phase II
- Journal Article
- Multicenter Study
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
Preserved source evidence · Not medical advice